阿茲海默症的緩解疾病藥物：全球市場

Disease-Modifying Therapies for Alzheimer's Disease: Global Markets

出版日期: 2025年06月23日 | 出版商:

BCC Research | 英文 65 Pages | 訂單完成後即時交付

價格

簡介目錄圖表

目前，阿茲海默症的緩解疾病藥物市場正處於早期發展階段。

這是因為第一種治療阿茲海默症的緩解疾病藥物（lecanemab）剛在2023年7月獲得美國FDA的核准。目前，多種緩解疾病正處於後期（2期及以後）臨床試驗中，如果核准，阿茲海默症緩解疾病藥物的市場可能會大幅擴大。

本報告調查了全球阿茲海默症緩解疾病藥物市場，並提供了全面的市場概述、市場影響因素和市場機會的分析、市場規模的趨勢和預測、各個細分市場和地區的詳細分析以及主要企業的概況。

Report Scope

Currently, the disease-modifying therapies (DMTs) market for Alzheimer's disease (AD) is in its early stage of development, as the first DMT for AD (lecanemab) was granted full approval by the U.S. FDA in July 2023. Several DMTs are in late-stage (phase 2 and above) clinical trials. If approved, they can expand the AD DMTs market significantly. BCC Research estimates market data for 2024 (the base year) and forecasts values for 2025 through 2030. Other than the approved products, the revenue forecast also considers the potential therapeutic candidates expected to enter during the forecast period and their targeted market potential.

The report analyzes the AD DMTs market by target type (anti-amyloid and other emerging targets), drug (Leqembi, Kisunla, and others), molecule type (large and small), and region (Asia-Pacific, North America, Europe, South America, the Middle East, and Africa).

Report Includes

Analysis of the current and future global market for disease-modifying therapies for Alzheimer's disease (AD)
Analyses of the global market trends, with market revenue data (sales figures) from 2023 to 2025, forecasts for 2026, and projected CAGRs through 2030
Estimates of the market's size and revenue prospects for the global market, accompanied by a market share analysis based on target type, drug type, drug molecule type, and region
Facts and figures pertaining to market dynamics, technological advancements, regulations, prospects, and the impacts of macroeconomic variables
Discussion of the underlying opportunities and potential in the disease-modifying therapies market
Information on products currently available for the diagnosis and treatment of Alzheimer's, as well as the promising new drug candidates and diagnostic imaging agents
Review of key marketed products, clinical trials, competitive scenario and R&D activities
An analysis of emerging trends and the industry structure, including companies' market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
Profiles of the leading companies

Chapter 1 Executive Summary

Market Outlook
Scope of Report
Market Summary

Chapter 2 Market Overview

Alzheimer's Disease Overview
Alzheimer's Disease Pathophysiology
Pharmaceutical Treatment of AD

Chapter 3 Market Dynamics

Market Dynamics Snapshot
Drivers
High Unmet Need in AD Treatment
Use of Biomarkers to Accelerate AD DMTs Approvals
Challenges
High Failure Rate in AD Drug Development
High Cost and Side Effects of Approved DMTs
Opportunity
DMTs for the Preclinical-Stage of AD

Chapter 4 Regulatory Landscape

U.S.
Standard Drug Approval Process
Expedited Approval Pathways
DMTs Approval Status by Country/ Region

Chapter 5 Emerging Technologies and Developments

A Multi-target Therapeutic Framework
Blood Tests for AD Screening and Diagnosis
Pipeline Analysis
Key Takeaways:
Small Molecule DMTs in Phase 3 Clinical Trials
Large Molecule DMTs in Phase 3 Clinical Trials

Chapter 6 Market Segment Analysis

Segmentation Breakdown
Market Analysis, by Target Type
Anti-Amyloid
Other Emerging Alzheimer's Pathology Targets for DMTs
Market Analysis, by Drug
Market Analysis, by Drug Molecule Type
Large Molecule
Small-Molecule
Geographic Breakdown
Market Analysis by Region
North America
Asia-Pacific
Europe
Middle East and Africa
South America

Chapter 7 Competitive Intelligence

Overview
Notable Companies Developing AD DMTs
Recent Developments/Strategic Analysis

Chapter 8 Appendix

Methodology
References
Abbreviations
Company Profiles
ALZHEON INC.
ANAVEX LIFE SCIENCES CORP.
ANNOVIS BIO INC.
BIOGEN
BIOVIE INC.
EISAI CO. LTD.
JOHNSON & JOHNSON SERVICES INC.
LILLY
NOVO NORDISK A/S
TAURX PHARMACEUTICALS LTD.

簡介目錄圖表

List of Tables

Summary Table : Global Market for DMTs for AD, by Region, Through 2030
Table 1 : Key Biomarkers Commonly Used to Evaluate and Support the Clinical Significance of AD DMTs
Table 2 : Recent Late-Stage Therapeutic Candidates Failures in Clinical Trials, 2025
Table 3 : DMTs Approval Status, by Country or Region, 2025
Table 4 : Selected Blood Tests in Development for AD Screening/Diagnosis
Table 5 : Disease-Modifying Small Molecule AD Drug Candidates in Phase 3 Clinical Trials
Table 6 : Disease-Modifying Large Molecule AD Drug Candidates in Phase 3 Clinical Trials
Table 7 : Global Market for DMTs for AD, by Target Type, Through 2030
Table 8 : Commercially Available Anti-Amyloid Drugs
Table 9 : Global Market for DMTs for AD, by Drug, Through 2030
Table 10 : Small Molecule versus Large Molecule Drugs
Table 11 : Global Market for DMTs for AD, by Drug Molecule Type, Through 2030
Table 12 : Global Market for DMTs for AD, by Region, Through 2030
Table 13 : Notable Companies Developing AD DMTs, 2025
Table 14 : Abbreviations Used in the Report
Table 15 : Alzheon Inc.: Company Snapshot
Table 16 : Alzheon Inc.: Product Portfolio
Table 17 : Alzheon Inc.: News/Key Developments, 2024
Table 18 : Anavex Life Sciences Corp.: Company Snapshot
Table 19 : Anavex Life Sciences Corp.: Financial Performance, FY 2023 and 2024
Table 20 : Anavex Life Sciences Corp.: Product Portfolio
Table 21 : Anavex Life Sciences Corp.: News/Key Developments, 2024
Table 22 : Annovis Bio Inc.: Company Snapshot
Table 23 : Annovis Bio Inc.: Financial Performance, FY 2023 and 2024
Table 24 : Annovis Bio Inc.: Product Portfolio
Table 25 : Biogen: Company Snapshot
Table 26 : Biogen: Financial Performance, FY 2023 and 2024
Table 27 : Biogen: Product Portfolio
Table 28 : Biogen: News/Key Developments, 2024 and 2025
Table 29 : BioVie Inc.: Company Snapshot
Table 30 : BioVie Inc.: Financial Performance, FY 2022 and 2023
Table 31 : BioVie Inc.: Product Portfolio
Table 32 : Eisai Co. Ltd.: Company Snapshot
Table 33 : Eisai Co. Ltd.: Financial Performance, FY 2023 and 2024
Table 34 : Eisai Co. Ltd.: Product Portfolio
Table 35 : Eisai Co. Ltd.: News/Key Developments, 2023-2025
Table 36 : Johnson & Johnson Services Inc.: Company Snapshot
Table 37 : Johnson & Johnson Services Inc.: Financial Performance, FY 2023 and 2024
Table 38 : Johnson & Johnson Services Inc.: Product Portfolio
Table 39 : Johnson & Johnson Services Inc.: News/Key Developments, 2024
Table 40 : Lilly: Company Snapshot
Table 41 : Lilly: Financial Performance, FY 2023 and 2024
Table 42 : Lilly: Product Portfolio
Table 43 : Lilly: News/Key Developments, 2024
Table 44 : Novo Nordisk A/S: Company Snapshot
Table 45 : Novo Nordisk A/S: Financial Performance, FY 2023 and 2024
Table 46 : Novo Nordisk A/S: Product Portfolio
Table 47 : TauRx Pharmaceuticals Ltd.: Company Snapshot
Table 48 : TauRx Pharmaceuticals Ltd.: Product Portfolio
Table 49 : TauRx Pharmaceuticals Ltd.: News/Key Developments, 2024

List of Figures

Summary Figure : Global Market Shares for DMTs for AD, by Region, 2024
Figure 1 : Disease-Modifying Therapies (DMTs) Market Snapshot for Alzheimer's Disease
Figure 2 : People Living with Dementia Around the World, 2020-2050
Figure 3 : Global Market Shares of DMTs for AD, by Region, 2024
Figure 4 : Global Market Shares of DMTs for AD, by Leading Companies, 2024
Figure 5 : Biogen: Revenue Shares, by Business Unit, FY 2024
Figure 6 : Biogen: Revenue Shares, by Country/Region, FY 2024
Figure 7 : Eisai Co. Ltd.: Revenue Shares, by Business Unit, FY 2024
Figure 8 : Eisai Co. Ltd.: Revenue Shares, by Country/Region, FY 2024
Figure 9 : Johnson & Johnson Services Inc.: Revenue Shares, by Business Unit, FY 2024
Figure 10 : Johnson & Johnson Services Inc.: Revenue Shares, by Country/Region, FY 2024
Figure 11 : Lilly: Revenue Shares, by Business Unit, FY 2024
Figure 12 : Lilly: Revenue Shares, by Country/Region, FY 2024
Figure 13 : Novo Nordisk A/S: Revenue Shares, by Business Unit, FY 2024
Figure 14 : Novo Nordisk A/S: Revenue Shares, by Country/Region, FY 2024